期刊文献+

前列腺癌:近期研究结果和新方向 被引量:3

Prostate cancer: recent findings and new directions
暂未订购
导出
摘要 虽然对临床局限性前列腺癌的最佳治疗手段尚未有定论,但针对不同患者应给予个体化治疗是目前前列腺癌临床治疗中的一致目标。近10年对前列腺癌的不断研究,临床上对前列腺癌的预防与早期诊断,以及依据治疗前各项实验室与影响学检查结果,对患者选择性地给予“等待观察”或积极治疗已取得了相当成就。本文就近10年来前列腺癌研究中一些最重要的研究结果与可能具显著发展前景的领域作一综述。 The best modality for the treatment of localized prostate cancer has not been determined; however, it is clear that individualized treatment will be necessary for the management of this malignancy. The diagnosis and treatment of prostate cancer have been the focus of clinical and radiological research in the past ten years, and it is clear that prostate cancer has diverse clinical behavior. Results of clinical researches have confirmed that some prostate cancer patients may benefit from conservative strategy such as "watchful-waiting" in stead of active treatment, while others will benefit from more aggressive combined treatment for their disease. Advances in the prostate cancer diagnosis, prevention and treatment will be summarized and reviewed in the following article.
出处 《中国癌症杂志》 CAS CSCD 2007年第3期188-192,共5页 China Oncology
关键词 前列腺癌 诊断 治疗 prostate cancer diagnosis treatment
  • 相关文献

参考文献43

  • 1Stamey TA,Johnstone IM,McNeal JE,et al.Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml.correlate poorly with post-radical prostatectomy cancer morphology:prostate specific antigen cure rates appear constant between 2 and 9 ng/ml[J].J Urol,2002,167:103-111.
  • 2Thompson IM,Goodman PJ,Tangen CM,et al.The influence of finasteride on the development of prostate cancer[J].N Engl J Med,2003,349:215-224.
  • 3Thompson IM,Pauler DK,Goodman PJ,et al.Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter[J].N Engl J Med,2004,350:2239-2246.
  • 4Roach M,3rd,Weinberg V,McLaughlin PW,et al.Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate[J].Urology,2003,61:730-735.
  • 5D'Amico AV,Chen MH,Roehl KA,et al.Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy[J].N Engl J Med,2004,351:125-135.
  • 6Roach M,3rd,Hanks G,Thames H,Jr,et al.Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer:Recommendations of the RTOG-ASTRO Phoenix Consensus Conference[J].Int J Radiat Oncol Biol Phys,2006,65:965-974.
  • 7D'Amico AV,Moul J,Carroll PR,et al.Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy[J].J Urol,2004,172:S42-6;discussion S46-7.
  • 8Jemal A,Siegel R,Ward E,et al.Cancer statistics,2007[J].CA Cancer J Clin,2007,57:43-66.
  • 9Johansson JE,Andren O,Andersson SO,et al.Natural history of early,localized prostate cancer[J].JAMA,2004,291:2713-2719.
  • 10Albertsen PC,Hanley JA,Gleason DF,et al.Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer[see comments][J].JAMA,1998,280:975-980.

同被引文献49

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部